Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F21%3A00541976" target="_blank" >RIV/61388963:_____/21:00541976 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20210216&DB=&locale=en_EP&CC=CA&NR=3029170C&KC=C&ND=4" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20210216&DB=&locale=en_EP&CC=CA&NR=3029170C&KC=C&ND=4</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
Original language description
Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use. The invention provides a new goup of substituted thienopyrrolopyrimidine ribonucleosides of general formula I, wherein R is defined in the claims. The compounds of this invention show strong cytostatic and cytotoxic activities preferably against cancer cell lines of broad spectrum of diseases including tumors of various histogenetic origin.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
CA3029170
Publisher
CA001 -
Publisher name
Canadian Intellectual Property Office (CIPO)
Place of publication
Gatineau, Québec
Publication country
CA - CANADA
Date of acceptance
Feb 16, 2021
Owner name
Ústav organické chemie a biochemie AV ČR, v. v. i. - Univerzita Palackého v Olomouci
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence